Weight-loss drug developer Metsera raises $275 million in US IPO
31/01/2025 24:01
Jan 30 (Reuters) - Weight-loss drug developer Metsera
has raised $275 million after pricing its U.S. initial public
offering at $18 per share, above its targeted range, the ARCH
Venture Partners-backed biotech company said on Thursday.
(Reporting by Prakhar Srivastava and Kanjyik Ghosh in
Bengaluru; Editing by Alan Barona)
((Prakhar.srivastava2@thomsonreuters.com))
Recent news on BioAge Labs
See all newsBrief: Bioage Labs Announces First Participant Dosed In Quell-Dme, A Phase 2 Trial Of Bge-102, A Novel Oral Nlrp3 Inhibitor, In Diabetic Macular Edema
BioAge Labs, Inc. reports results for the quarter ended June 30 - Earnings Summary
BioAge Labs Q1 collaboration revenue beats estimates on Novartis collaboration
BioAge Labs full-year collaboration revenue beats estimates
U.S. RESEARCH ROUNDUP-Chevron, GoDaddy, HP